Abstract
Background: The objective of the present study was to design a porous osmotic pump-based drug delivery system for the controlled release of captopril (Cap) which can maintain a constant therapeutic concentration, thus reducing dose-related side effects and dosing frequency. Methods: The study evaluated in vitro drug release for the controlled porosity osmotic pump tablet (CPOPT) of Cap. This in vitro drug release study investigated the influence of the tablet formulation variables such as the amount of mannitol, hydroxypropylmethylcellulose K4M (HPMCK4M), and polyvinyl pyrrolidone (PVP K-30) in the core and the concentration of cellulose acetate and polyethylene glycol 400 (PEG-400) in the coating solution. Results: It was found that the drug release was mostly affected by the amount of mannitol, HPMCK4M, and PVP K-30 in the core and the amount of cellulose acetate and PEG-400 in the coating solution. Conclusion: In general, the objective of the study was established by coating the core tablet containing osmotic and pore-forming agents. Therefore, the CPOPT of Cap could be a safe, effective, stable, and promising preparation in the future.
Highlights
The objective of the present study was to design a porous osmotic pump-based drug delivery system for the controlled release of captopril (Cap) which can maintain a constant therapeutic concentration, reducing dose-related side effects and dosing frequency
Osmosis is an aristocratic biophenomenon, which is exploited for the development of delivery systems with every desirable property of an ideal controlled drug delivery system
The release rate was found to decrease by an increase in the concentration of hydroxypropylmethylcellulose K4M (HPMCK4M) and PVP K-30
Summary
The objective of the present study was to design a porous osmotic pump-based drug delivery system for the controlled release of captopril (Cap) which can maintain a constant therapeutic concentration, reducing dose-related side effects and dosing frequency. Oral controlled release dosage forms have been developed over the past three decades due to their considerable therapeutic advantages including ease of administration, patient compliance, and flexibility in formulation. This approach is limited due to several constraints including the inability to restrain and locate the controlled drug delivery system within the desired region of the gastrointestinal tract due to variable gastric emptying and motility (2). An osmotic pump tablet generally consists of a core containing the drug, an osmotic agent, other excipients, and a semipermeable membrane (SPM) coat (5)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
